Dinu Valentin Balanescu
Overview
Explore the profile of Dinu Valentin Balanescu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
116
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pushparaji B, Donisan T, Balanescu D, Park J, Monlezun D, Ali A, et al.
Curr Treat Options Cardiovasc Med
. 2023 May;
25(6):143-158.
PMID: 37143711
Purpose Of Review: The treatment of coronary artery disease (CAD) in cancer patients is an evolving landscape. Recent data emphasizes the importance of aggressive management of cardiovascular risk factors and...
2.
Jacob R, Palaskas N, Lopez-Mattei J, Hassan S, Kim P, Donisan T, et al.
JACC CardioOncol
. 2021 Oct;
3(3):452-456.
PMID: 34604808
No abstract available.
3.
Aziz M, Herrmann J, Marmagkiolis K, Balanescu D, Donisan T, Pushparaji B, et al.
Front Cardiovasc Med
. 2021 Jun;
8:665303.
PMID: 34164440
This study assessed stent healing patterns and cardiovascular outcomes by optical coherence tomography (OCT) in cancer patients after drug-eluting stent (DES) placement. Cancer treatment, owing to its cytotoxic and antiproliferative...
4.
Donisan T, Balanescu D, Iliescu C, Balanescu S
Tex Heart Inst J
. 2021 Jun;
48(2).
PMID: 34139762
No abstract available.
5.
Balanescu D, Aziz M, Donisan T, Palaskas N, Lopez-Mattei J, Hassan S, et al.
Coron Artery Dis
. 2020 Nov;
32(4):295-301.
PMID: 33196581
Objective: Percutaneous coronary intervention (PCI) with new-generation drug-eluting stents (DESs) may provide survival benefits to the cancer population undergoing PCI by expediting cancer treatment due to improved safety profile. We...
6.
Transcatheter and surgical aortic valve replacement impact on outcomes and cancer treatment schedule
Gill C, Lee M, Balanescu D, Donisan T, Serauto Canache A, Palaskas N, et al.
Int J Cardiol
. 2020 Aug;
326:62-70.
PMID: 32858137
Background: Recent data suggest that transcatheter aortic valve replacement (TAVR) for the treatment of severe aortic stenosis (AS) is viable in cancer patients. TAVR may be preferred in cancer patients...
7.
Balanescu D, Donisan T, Deswal A, Palaskas N, Song J, Lopez-Mattei J, et al.
Int J Cardiol
. 2020 Apr;
313:1-8.
PMID: 32320781
Background: The benefits of invasive versus noninvasive management in oncology patients with acute myocardial infarction (AMI) are unclear. We aimed to retrospectively determine outcome differences between conservative and invasive management...
8.
Balanescu D, Donisan T, Palaskas N, Lopez-Mattei J, Kim P, Buja L, et al.
Cardiovasc Pathol
. 2020 Apr;
47:107211.
PMID: 32268262
Immune checkpoint inhibitor (ICI)-induced myocarditis carries a poor prognosis and is not fully understood. Similar to lymphocytic myocarditis and acute cellular rejection in heart transplant, ICI-induced myocarditis requires immune suppressive...
9.
Agha A, Gill C, Balanescu D, Donisan T, Palaskas N, Lopez-Mattei J, et al.
Front Cardiovasc Med
. 2020 Mar;
7:9.
PMID: 32118047
To evaluate the role of platelet count and thromboelastogram (TEG) in the treatment of thrombocytopenic cancer patients with suspected coronary artery disease (CAD). Cancer patients with CAD and thrombocytopenia are...
10.
Donisan T, Balanescu D, Palaskas N, Lopez-Mattei J, Karimzad K, Kim P, et al.
Cardiol Clin
. 2019 Oct;
37(4):469-486.
PMID: 31587788
Comorbidities specific to the cardio-oncology population contribute to the challenges in the interventional management of patients with cancer and cardiovascular disease (CVD). Patients with cancer have generally been excluded from...